Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746074 | 1.00 | TDP1 (0.45) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL27553649 | 0.81 | TDP1 (0.50) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL11274670 | 0.81 | CYP4F2 (0.51) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL11274669 | 0.81 | CYP4F2 (0.51) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL6747017 | 0.81 | LMNA (0.49) | TDP1GLAMAOBLMNANPC1 | |
| SCHEMBL6747013 | 0.81 | LMNA (0.49) | TDP1GLAMAOBLMNANPC1 | |
| SCHEMBL9512416 | 0.79 | CYP3A4 (0.49) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL27211827 | 0.77 | TDP1 (0.49) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL27211734 | 0.77 | TDP1 (0.49) | TDP1GLAPAMMAOBLMNA | |
| SCHEMBL27211775 | 0.77 | TDP1 (0.49) | TDP1GLAPAMMAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720445-B2 | PHENYLPROPIOLOYLOXYMETHYL ACETATE, FOR EXAMPLE; TREATING CANCER, HEMOLOGICAL DISORDERS AND INHERITED METABOLIC DISORDERS; INHIBITORS OF HISTONE DEACETYLASE | BEACON LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6699902-B2 | ANTICANCER AGENTS | BEACON LABORATORIES, INC. | 2004-03-02 | — | — | US | disclosed |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | ERRANT GENE THERAPEUTICS, LLC | 2002-10-31 | — | — | US | disclosed |
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | BEACON LABORATORIES, A DELAWARE CORPORATION | 2002-08-29 | — | — | US | disclosed |
| EP-1216984-A1 | Novel acetyloxymethyl esters and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | AADAC, ACAT1, EP300 | TDP1 1069/4885GLA 94/4885PAM 3182/4885 |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | AADAC, ACAT1, EP300 | TDP1 1069/4885GLA 94/4885PAM 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.